Mark Niosi

1.4k citations
22 papers · 542 · h-index 13

Impact in

  • Pharmacology top 2%
    • Pharmacogenetics and Drug Metabolism
    • Drug-Induced Hepatotoxicity and Protection
  • Physiology top 10%
    • Adenosine and Purinergic Signaling
    • Pain Mechanisms and Treatments

Papers in

  • Oncology 14
    • Drug Transport and Resistance Mechanisms 13
  • Pharmacology 13
    • Pharmacogenetics and Drug Metabolism 12
Co-authors
Jian Lin (8 shared papers)Li Di (7 shared papers)Keith Riccardi (6 shared papers)Phillip D. Yates (1 shared paper)Manthena V. S. Varma (3 shared papers)Cheng Chang (1 shared paper)Rachel E. Kosa (3 shared papers)Theunis C. Goosen (5 shared papers)
Journals
Drug Metabolism and Disposition (13 papers)Journal of Pharmaceutical Sciences (1 paper)Journal of Pharmacology and Experimental Therapeutics (1 paper)Drug Metabolism and Pharmacokinetics (1 paper)Bioorganic & Medicinal Chemistry (1 paper)
Partner nations
United StatesUnited KingdomCanada

In The Last Decade

Mark Niosi

21 papers receiving 535 citations

Peers

Mark Niosi
Comparison fields: 5 of 85
  • Pharmacology 209
  • Physiology 48
  • Oncology 238
  • Pediatrics, Perinatology and Child Health 97
  • Biochemistry 28
Replace Atsushi Ose with:
Atsushi Ose Japan
William Neway United States
Stella Vincent United States
Iain Martin United Kingdom
Kazutomi Kusano Japan
Bahman M. Sadeghpour Italy
Claire Denizot France
Wataru Kishimoto Japan
Yvonne Gloor Switzerland
Xiao-Hui Guo China
Mark Niosi relative to Atsushi Ose Japan Atsushi Ose's profile →
Citations per field
00.5×2×4×6×
Atsushi Ose · 1×
Citations per year

Countries citing papers authored by Mark Niosi

Since Specialization
Citations

This map shows the geographic impact of Mark Niosi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Niosi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Niosi more than expected).

Fields of papers citing papers by Mark Niosi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Niosi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Niosi. The network helps show where Mark Niosi may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Niosi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Niosi Line = papers co-authored together Mark Niosi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Plasma Protein Binding of Challenging Compounds
Journal of Pharmaceutical Sciences ·Keith Riccardi, Shannon Cawley, Phillip D. Yates, Cheng Chang, Carrie Funk, Mark Niosi, Jian Lin, Li Di
201586
2
A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats
European Journal of Pharmacology ·Gang Wu, Garth T. Whiteside, Gary Lee, Scott Nolan, Mark Niosi, Michelle Pearson, Victor I. Ilyin
200464
3
Utility of the carboxylesterase inhibitorbis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor
Xenobiotica ·Heather Eng, Mark Niosi, Thomas S. McDonald, Angela Wolford, Y. Chen, S. T. M. Simila, Jonathan Bauman, Joseph S. Warmus, Amit S. Kalgutkar
201053
4
Organic Anion Transporter 2–Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability–Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs
Journal of Pharmacology and Experimental Therapeutics ·Emi Kimoto, Sumathy Mathialagan, Laurie Tylaska, Mark Niosi, Jian Lin, Anthony Carlo, David A. Tess, Manthena V. S. Varma
201846
5
Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes
Drug Metabolism and Disposition ·Keith Riccardi, Jian Lin, Zhenhong Li, Mark Niosi, Sangwoo Ryu, Wenyi Hua, Karen Atkinson, Rachel E. Kosa, John Litchfield, Li Di
201742
6
Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance
Drug Metabolism and Disposition ·Tom De Bruyn, Ayşe Ufuk, Carina Cantrill, Rachel E. Kosa, Yi-An Bi, Mark Niosi, Sweta Modi, A. David Rodrigues, Larry M. Tremaine, Manthena V. S. Varma, Aleksandra Galetin, J. Brian Houston
201840
7
Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides
Drug Metabolism and Disposition ·Rhishikesh Thakare, Hongying Gao, Rachel E. Kosa, Yi-An Bi, Manthena V. S. Varma, Matthew A. Cerny, Raman Sharma, Max Kühn, Bingshou Huang, Yiping Liu, Aijia Yu, Gregory S. Walker, Mark Niosi, Larry M. Tremaine, Yazen Alnouti, A. David Rodrigues
201738
8
Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity
Drug Metabolism and Disposition ·Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J. Novak, John K. Fallon, Jill Barber, Philip C. Smith, Amin Rostami‐Hodjegan, Theunis C. Goosen
201736
9
Determination of Unbound Partition Coefficient and in Vitro–in Vivo Extrapolation for SLC13A Transporter–Mediated Uptake
Drug Metabolism and Disposition ·Keith Riccardi, Zhongrui Li, Janice A. Brown, Matthew Gorgoglione, Mark Niosi, J Gosset, Kim Huard, Derek M. Erion, Li Di
201623
10
Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5′-Diphosphate–Glucuronosyltransferase Enzymes with Reference to Catalytic Activity
Drug Metabolism and Disposition ·Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J. Novak, Zubida M. Al‐Majdoub, Theunis C. Goosen, Amin Rostami‐Hodjegan, Jill Barber
201821
11
A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects
Drug Metabolism and Disposition ·Rui Li, Mark Niosi, Nathaniel Johnson, David A. Tess, Emi Kimoto, Jian Lin, Xin Yang, Keith Riccardi, Sangwoo Ryu, Ayman El‐Kattan, Tristan S. Maurer, Larry M. Tremaine, Li Di
201818
12
Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor
Bioorganic & Medicinal Chemistry ·Robert L. Dow, Melissa P. Andrews, Jiancheng Li, E. Michael Gibbs, Angel Guzmán-Pérez, Jennifer L. LaPerle, Qifang Li, Dawn Mather, Michael J. Munchhof, Mark Niosi, Leena Patel, Christian Perreault, Susan Tapley, William J. Zavadoski
201317
13
In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes
Drug Metabolism and Disposition ·Kimberly Lapham, Ernesto Callegari, Julie Cianfrogna, Jian Lin, Mark Niosi, Christine C. Orozco, Raman Sharma, Theunis C. Goosen
202016
14
2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety
Journal of Medicinal Chemistry ·Robert L. Dow, Mark Ammirati, Scott W. Bagley, Samit K. Bhattacharya, Leonard Buckbinder, Christian Cortés‐Campos, Ayman El‐Kattan, Kristen K. Ford, Gary B. Freeman, Cristiano R. W. Guimarães, Shenping Liu, Mark Niosi, Athanasia Skoura, David A. Tess
201810
15
A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 2: Prospectively Predicting Systemic and Liver Exposure in Healthy Subjects
Drug Metabolism and Disposition ·Rui Li, Emi Kimoto, Mark Niosi, David A. Tess, Jian Lin, Larry M. Tremaine, Li Di
20187
16
Novel in vitro method to predict in vivo liver-to-plasma unbound partition coefficient
Drug Metabolism and Pharmacokinetics ·Li Di, Keith Riccardi, Zhenhong Li, Jian Lin, Sangwoo Ryu, Mark Niosi
20186
17
6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to β-Estradiol
Drug Metabolism and Disposition ·Kimberly Lapham, Jian Lin, Jonathan J. Novak, Christine C. Orozco, Mark Niosi, Li Di, Theunis C. Goosen, Sangwoo Ryu, Keith Riccardi, Heather Eng, Kimberly O. Cameron, Amit S. Kalgutkar
20185
18
A Sensitive Method for the Quantitation of the Peptide-Based Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Plasma Using Microfluidics Chromatography Tandem MS
Bioanalysis ·Amanda King‐Ahmad, Amit S. Kalgutkar, Mark Niosi, Heather Eng, Christopher L. Holliman
20185
19
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite
Drug Metabolism and Disposition ·Martin E. Dowty, Ruolun Qiu, Alyssa Dantonio, Mark Niosi, Angela C. Doran, Amanda Balesano, Stephen W. Wright, Gregory S. Walker, Raman Sharma
20244
20
Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2′-O-Glucuronide Formation as a Selective UGT2B4 Probe Reaction
Drug Metabolism and Disposition ·Kimberly Lapham, Nicholas Ferguson, Mark Niosi, Theunis C. Goosen
20243

About Mark Niosi

Mark Niosi is a scholar working on Oncology, Pharmacology, Molecular Biology, Pediatrics, Perinatology and Child Health and Surgery, having authored 22 papers that have together received 542 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (13 papers), Pharmacogenetics and Drug Metabolism (12 papers), Pharmacological Effects and Toxicity Studies (5 papers), Pancreatic function and diabetes (2 papers), Metabolism, Diabetes, and Cancer (2 papers), Cancer therapeutics and mechanisms (2 papers), Neuropeptides and Animal Physiology (2 papers) and Receptor Mechanisms and Signaling (2 papers). The work is most often cited by research in Pharmacology (209 citations), Physiology (48 citations), Oncology (238 citations), Pediatrics, Perinatology and Child Health (97 citations) and Biochemistry (28 citations). Mark Niosi has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Jian Lin, Li Di, Keith Riccardi, Phillip D. Yates, Manthena V. S. Varma, Cheng Chang, Rachel E. Kosa, Theunis C. Goosen, Garth T. Whiteside and Gary Lee. Their work appears in journals such as Drug Metabolism and Disposition, Journal of Pharmaceutical Sciences, Journal of Pharmacology and Experimental Therapeutics, Drug Metabolism and Pharmacokinetics and Bioorganic & Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atsushi OseBreakdown of academic impact, for papers by William NewayBreakdown of academic impact, for papers by Stella VincentBreakdown of academic impact, for papers by Iain MartinBreakdown of academic impact, for papers by Kazutomi KusanoBreakdown of academic impact, for papers by Bahman M. SadeghpourBreakdown of academic impact, for papers by Claire DenizotBreakdown of academic impact, for papers by Wataru KishimotoBreakdown of academic impact, for papers by Yvonne GloorBreakdown of academic impact, for papers by Xiao-Hui Guo